Overview Request Sample Pages Request Customization Download PDF
You are viewing: Asia Pacific Preimplantation Genetic Testing Market analysis

The Asia Pacific Preimplantation Genetic Testing Market was valued at $95 Million in 2025 and projected to reach to $170.3 Million by 2030, representing a compound annual growth rate of 12.4%. The Asia Pacific preimplantation genetic testing market is positioned for substantial growth through 2030, with the market expanding from $95.0 million in 2025 to $170.3 million by 2030.

Asia Pacific Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Preimplantation Genetic Testing Market Trends and Insights

  • Asia Pacific's market growth is driven by rising infertility rates, increasing adoption of assisted reproductive technologies, and growing awareness of genetic screening benefits among couples in the region.
  • The 12.4% compound annual growth rate in Asia Pacific significantly outpaces global trends, reflecting the region's expanding healthcare infrastructure and rising disposable incomes. Asia Pacific's preimplantation genetic testing market is characterized by increasing demand from developed economies such as Australia, Japan, and South Korea, alongside emerging opportunities in India and Southeast Asia.
  • Regulatory frameworks in Asia Pacific are gradually becoming more supportive of genetic testing, and fertility clinics across the region are investing in advanced PGT technologies.
  • The forecast period through 2030 will see Asia Pacific strengthen its position as a high-growth market, driven by demographic shifts, improved access to fertility services, and enhanced clinical adoption of genetic screening protocols..

Key Market Statistics

  • CAGR (2025-2030) 12.4% CAGR
  • Market Size, 2025 ~USD 95 Million
  • Forecast, 2030 ~USD 170.3 Million
  • Geography Asia Pacific

Asia Pacific Preimplantation Genetic Testing Market Overview

Rapid Market Expansion :

Asia Pacific's preimplantation genetic testing market is growing at 12.4% CAGR, outpacing the global rate of 10.5%, driven by increasing demand for advanced reproductive technologies across the region.

Rising Infertility Awareness :

Growing infertility rates and increased adoption of assisted reproductive technologies (ART) in Asia Pacific are propelling couples to seek genetic screening solutions for healthier pregnancies.

China's Market Leadership :

China dominates the Asia Pacific region with a market size of $64.6 million, reflecting strong healthcare infrastructure investments and high demand for genetic testing services among affluent populations.

Emerging Market Opportunities :

India and Japan represent significant growth opportunities with market sizes of $25.6 million and $42.3 million respectively, supported by improving healthcare access and rising genetic awareness.

Asia Pacific Preimplantation Genetic Testing Market Dynamics

  • This expansion is fueled by demographic shifts, including delayed childbearing and increased infertility prevalence across major economies like China, Japan, and India.
  • Healthcare infrastructure improvements and rising disposable incomes are enabling broader access to advanced reproductive technologies. Regulatory frameworks are gradually becoming more supportive of genetic testing in assisted reproduction, particularly in developed Asia Pacific markets.
  • The convergence of technological advancement, growing medical awareness among couples, and improving reimbursement policies will continue to drive market penetration.
  • Emerging economies within the region present untapped potential as healthcare systems modernize and genetic screening becomes more affordable and accessible..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Asia Pacific PGT market valued at $95.0M in 2025, expanding to $170.3M by 2030 at 12.4% CAGR
      • Asia Pacific growth outpaces global average, driven by rising infertility and ART adoption across the region
      • Asia Pacific's developed markets (Japan, Australia, South Korea) lead adoption, while emerging economies present untapped potential
      • Regulatory support and clinic investment in Asia Pacific are accelerating PGT technology deployment through 2030

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Asia Pacific Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      Target Audience

      • Fertility Clinic Operators : Fertility clinics and ART centers across Asia Pacific need market intelligence to understand demand trends, competitive positioning, and growth opportunities in genetic testing services within their regions.
      • Diagnostic Laboratory Companies : Genetic testing laboratories and diagnostic service providers require Asia Pacific market data to identify expansion opportunities, assess market saturation, and develop region-specific service offerings.
      • Medical Device & Biotech Manufacturers : Companies developing PGT technologies and genetic screening platforms need Asia Pacific market insights to guide product development, regulatory strategy, and commercialization timelines.
      • Healthcare Investors & PE Firms : Investment firms evaluating opportunities in Asia Pacific reproductive healthcare require detailed market analysis, growth projections, and country-level performance data for investment decision-making.
      • Healthcare Policy & Government Bodies : Regulatory agencies and healthcare policymakers in Asia Pacific countries need market research to inform genetic testing regulations, reimbursement policies, and healthcare infrastructure planning.

      Key Companies in the Asia Pacific Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Asia Pacific vs. other regions

      HowAsia Pacific compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 350 Million · 10.1% wtd CAGR ·
      Europe
      ~USD 211.4 Million · 11.2% wtd CAGR ·
      Latin America
      ~USD 29.5 Million · 9.4% wtd CAGR ·
      Middle East
      ~USD 14.8 Million · 8.8% wtd CAGR ·

      Countries within Asia Pacific - compare and drill down

      Country2025 size (native)
      ChinaUSD 64.6 Million
      JapanUSD 42.3 Million
      IndiaUSD 25.6 Million
      AustraliaUSD 6.7 Million
      South KoreaUSD 8.2 Million
      Rest Of Asia PacificUSD 22.7 Million

      Country market size visualization

      China
      USD 64.6 Million
      Japan
      USD 42.3 Million
      India
      USD 25.6 Million
      Australia
      USD 6.7 Million
      South Korea
      USD 8.2 Million
      Rest Of Asia Pacific
      USD 22.7 Million

      Reasons to Buy this Report

      • Regional Market Segmentation : Gain detailed insights into Asia Pacific's preimplantation genetic testing market with country-level breakdowns for China, Japan, India, Australia, and South Korea to identify high-growth opportunities.
      • Competitive Landscape Analysis : Understand market dynamics specific to Asia Pacific, including key players, emerging competitors, and strategic positioning within the region's rapidly evolving reproductive genetics sector.
      • Growth Driver Identification : Access comprehensive analysis of region-specific factors driving market expansion, including infertility trends, ART adoption rates, regulatory developments, and healthcare infrastructure improvements.
      • Investment & Expansion Strategy : Leverage Asia Pacific market forecasts and country-level data to develop targeted expansion strategies, identify partnership opportunities, and allocate resources effectively across the region.
      • Regulatory & Reimbursement Insights : Obtain critical information on Asia Pacific regulatory frameworks, reimbursement policies, and healthcare system variations that impact market accessibility and pricing strategies by country.

      Frequently asked questions

      What is the current market size of preimplantation genetic testing in Asia Pacific?

      The Asia Pacific preimplantation genetic testing market was valued at $95.0 million in 2025 and is expected to grow to $170.3 million by 2030.

      What is the projected growth rate for Asia Pacific's PGT market?

      Asia Pacific's preimplantation genetic testing market is projected to grow at a compound annual growth rate (CAGR) of 12.4% from 2025 to 2030.

      Which countries in Asia Pacific are driving PGT market growth?

      Developed markets in Asia Pacific including Japan, Australia, and South Korea are leading adoption, while India and Southeast Asian nations represent emerging growth opportunities.

      What factors are accelerating PGT adoption in Asia Pacific?

      Rising infertility rates, increased ART adoption, growing awareness of genetic screening, improving regulatory frameworks, and expanding healthcare infrastructure are key drivers in Asia Pacific.

      How does Asia Pacific's PGT market growth compare to global trends?

      Asia Pacific's 12.4% CAGR significantly outpaces the global market CAGR of 10.5%, positioning the region as a high-growth market through 2030.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status